TuHURA Biosciences, Inc. announced a registered direct offering of $15.6 million in shares and warrants.
The offering includes the purchase of 9,462,423 shares of common stock and accompanying warrants at $1.65 per share.
The closing of the offering is expected to occur in three tranches, with the first closing on December 10, 2025.
Offering Details
Includes 9,462,423 shares of common stock and Series A/B warrants at specific prices.
Placement Agents
H.C. Wainwright & Co. and Rodman & Renshaw LLC are acting as lead and co-placement agents, respectively.
Closing Timelines
Three tranches expected to close in December 2025, January 2026, and February 2026.
Gross Proceeds Breakdown
Approximately $8.6 million from the first closing, $5 million from the second closing, and $2 million from the third closing.
Intended Use of Proceeds
Will be utilized for working capital, bridge note repayment, and general corporate purposes.
- The offering aims to raise significant funds to support TuHURA Biosciences' immuno-oncology developments.
- Proceeds are earmarked for crucial operational needs and financial obligations, including bridge note repayment.
TuHURA Biosciences' registered direct offering is a strategic move to secure funding for its immuno-oncology projects and essential financial obligations.